Dr. Nagababu Enika, PhD
Claim this profileMore about Nagababu Enika, PhD
Clinical Trial Related
1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Nagababu Enika, PhD has experience with
- Mixture Of Sodium Nitrite And N-acetylcysteine (NAC) Crystals
Breakdown of trials Nagababu Enika, PhD has run
Cardiovascular Disease
Hypertension
High Blood Pressure
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nagababu Enika, PhD specialize in?
Nagababu Enika, PhD focuses on Cardiovascular Disease and Hypertension. In particular, much of their work with Cardiovascular Disease has involved treating patients, or patients who are undergoing treatment.
Is Nagababu Enika, PhD currently recruiting for clinical trials?
No, Nagababu Enika, PhD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Nagababu Enika, PhD has studied deeply?
Yes, Nagababu Enika, PhD has studied treatments such as Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crystals.
What is the best way to schedule an appointment with Nagababu Enika, PhD?
Apply for one of the trials that Nagababu Enika, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.